Neuren Pharmaceuticals Limited (ASX:NEU)
Australia
· Delayed Price · Currency is AUD 12.75
+1.07 (9.16%)
Mar 10, 2026, 1:59 PM AEST
Neuren Pharmaceuticals Balance Sheet
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 4.23 | 3.15 | 17.09 | 40.18 | 36.78 | Upgrade
|
| Short-Term Investments | 291.9 | 219.09 | 211.45 | - | - | Upgrade
|
| Cash & Short-Term Investments | 296.12 | 222.24 | 228.54 | 40.18 | 36.78 | Upgrade
|
| Cash Growth | 33.24% | -2.76% | 468.79% | 9.23% | 52.07% | Upgrade
|
| Accounts Receivable | 19.37 | 172.91 | 12.8 | - | 0.01 | Upgrade
|
| Other Receivables | 7.17 | 2.42 | 1.61 | 1.09 | 1.42 | Upgrade
|
| Receivables | 26.54 | 175.33 | 14.41 | 1.09 | 1.42 | Upgrade
|
| Prepaid Expenses | 9.57 | 0.4 | 4.21 | 1.98 | 1.84 | Upgrade
|
| Other Current Assets | - | 1.36 | - | - | - | Upgrade
|
| Total Current Assets | 332.23 | 399.33 | 247.16 | 43.25 | 40.04 | Upgrade
|
| Property, Plant & Equipment | 0.05 | 0.03 | 0.04 | 0.02 | 0.01 | Upgrade
|
| Long-Term Deferred Tax Assets | 10.58 | 10.35 | 0.77 | - | - | Upgrade
|
| Total Assets | 342.86 | 409.71 | 247.97 | 43.27 | 40.06 | Upgrade
|
| Accounts Payable | 0.88 | 1.45 | 0.68 | 0.26 | 0.25 | Upgrade
|
| Accrued Expenses | 1.53 | 1.45 | 2.74 | 0.72 | 0.56 | Upgrade
|
| Current Income Taxes Payable | - | 42.87 | 37.12 | - | - | Upgrade
|
| Other Current Liabilities | 1.94 | - | 2.23 | 0.7 | - | Upgrade
|
| Total Current Liabilities | 4.34 | 45.76 | 42.76 | 1.68 | 0.8 | Upgrade
|
| Pension & Post-Retirement Benefits | 0.07 | 0.04 | - | - | - | Upgrade
|
| Total Liabilities | 4.41 | 45.8 | 42.76 | 1.68 | 0.8 | Upgrade
|
| Common Stock | 134.94 | 165.27 | 173.13 | 167.74 | 167.58 | Upgrade
|
| Retained Earnings | 210.87 | 180.43 | 38.39 | -118.69 | -118.88 | Upgrade
|
| Comprehensive Income & Other | -7.36 | 18.2 | -6.31 | -7.46 | -9.45 | Upgrade
|
| Shareholders' Equity | 338.45 | 363.9 | 205.21 | 41.59 | 39.25 | Upgrade
|
| Total Liabilities & Equity | 342.86 | 409.71 | 247.97 | 43.27 | 40.06 | Upgrade
|
| Net Cash (Debt) | 296.12 | 222.24 | 228.54 | 40.18 | 36.78 | Upgrade
|
| Net Cash Growth | 33.24% | -2.76% | 468.79% | 9.23% | 52.07% | Upgrade
|
| Net Cash Per Share | 2.26 | 1.70 | 1.75 | 0.31 | 0.31 | Upgrade
|
| Filing Date Shares Outstanding | 126.64 | 127.01 | 127.27 | 125.97 | 125.97 | Upgrade
|
| Total Common Shares Outstanding | 126.64 | 127.01 | 127.27 | 125.97 | 125.97 | Upgrade
|
| Working Capital | 327.9 | 353.57 | 204.39 | 41.57 | 39.24 | Upgrade
|
| Book Value Per Share | 2.67 | 2.87 | 1.61 | 0.33 | 0.31 | Upgrade
|
| Tangible Book Value | 338.45 | 363.9 | 205.21 | 41.59 | 39.25 | Upgrade
|
| Tangible Book Value Per Share | 2.67 | 2.87 | 1.61 | 0.33 | 0.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.